Rocket Lab stock surges 396% in a year: the real story

Rocket Lab reported Q1 2026 revenue of $200.35 million, up 63.4% year over year and above the $189.65 million consensus, while EPS of -$0.07 matched estimates and guidance was raised. Two top-ranked analysts lifted price targets to a Street-high $120, and the stock jumped 34% after the results, with shares near $105.31 versus a 52-week low of $20.88. Bookings were especially strong, including 31 Electron/HASTE orders, a $190 million HASTE deal, and 5 Neutron bookings, while the Mynaric acquisition and $816 million SDA contract add to the growth runway.

Analysis

This is less a one-quarter beat than a regime change in how the market should underwrite the business. The mix shift matters: launch bookings and government backlog are starting to de-risk the cadence narrative, while Neutron introduces a second valuation engine that can re-rate the stock from a “small launch provider” to a vertically integrated space infrastructure platform. The market is now paying for a 2027–2028 operating model in which launch is no longer the sole swing factor; that expands the multiple, but it also makes execution on integration and margin mix much more important.

The near-term second-order effect is margin compression disguised as growth. New low-margin revenue streams can create the illusion of accelerating scale while depressing segment profitability, which means the stock is now more sensitive to any sign that subsystems and higher-value components fail to offset the mix drag. In other words, the market is rewarding topline visibility today, but it will punish even modest slippage in gross margin trajectory once the easy booking momentum fades and investors begin to focus on conversion, not just contract wins.

The biggest catalyst path is binary and time-bound: Neutron’s first launch and early cadence over the next 6–9 months. A clean debut would likely force another wave of estimate revisions and multiple expansion; a delay would not just hurt revenue timing, it would challenge the narrative that Rocket Lab can scale into the larger launch market without repeated schedule friction. The setup is therefore bullish, but increasingly crowded—when a stock has already re-rated this violently, the next 15% upside is usually easier to capture than the next 15% downside, while the downside if Neutron slips can be much larger and much faster.

The consensus may be underestimating how much institutional ownership can amplify both directions. Large holders have been adding, which supports the stock in the near term, but it also means incremental disappointment could trigger mechanical de-risking if the story shifts from “category winner” to “execution risk.” That makes this an attractive momentum-with-catalyst trade, but a poor place to be complacent on valuation.

Key Decisions for Investors

• Long RKLB on pullbacks over the next 2-4 weeks with a tactical target near the new Street-high area; risk/reward is still favorable while Neutron remains on-schedule, but size modestly because upside is increasingly dependent on flawless execution.
• Buy RKLB Jan-2027 call spreads to express Neutron cadence upside while limiting valuation compression risk; this is the cleanest way to play a successful first launch and 2027 revenue re-rating.
• Hedge any long RKLB equity with a short-dated put spread into the Neutron launch window; if the program slips, the stock should re-rate sharply lower as the market derates the 2027 revenue bridge.
• Relative-value long RKLB / short a basket of lower-growth aerospace-defense primes over 3-6 months if you want exposure to space secular growth without paying for the same launch optionality embedded in the big contractors.
• If margin commentary deteriorates for two consecutive quarters, trim 30-50% of exposure; the market is currently forgiving of mix drag, but that tolerance will vanish once cadence becomes the main debate.